Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

NCT04418466 | Completed Phase 1 Results FDA Drug FDA Device

• 2 other identifiers: DLP-114-03R44MH094036
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 2

Brief Summary

This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).

Conditions

Schizophrenia

Keywords

risperidone; schizophrenia; implant

Outcome Measures

Primary Outcomes (3)

• Adverse Events

  Number of Participants with Treatment-Emergent Adverse Events.

  Up to 8 months and up to 15 months for groups 1 and 2 respectively.

• Percentage of Implant Site Assessments With a Dermal Irritation Scale Rating Greater Than Zero

  Evaluate the incidence of local site reactions. Percentage of implant site assessments with a dermal irritation scale rating greater than zero (rating scale is 0 to 4, where 0 indicates no erythema or edema, and 4 indicates erythema or slight eschar).

  6 months and 12 months for groups 1 and 2 respectively.

• Number of Participants Who Experienced an AE Related to Implantation or Explantation Procedures

  Number of participants who experienced an Adverse Events related to Implantation or Explantation Procedures

  6 months and 12 months for groups 1 and 2 respectively.

Secondary Outcomes (7)

• Oral Phase Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During 24 Hours After 3 Days of Repeated 3mg QD Oral Administrations

  t=0, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours following oral administration.

• Implant Cave: Average Plasma Concentration of Active Moiety (Risperidone + 9 OH Risperidone) During the Implant Phase

  PK blood draw & analysis were performed per protocol time intervals; 0, 1, 2, 3, 4, 6, 8, 12, 24, 28, 32, 36, 48, and 52 hours post-placement of implants; 1x/day for 4 additional days, 1x/week during days 5-28; biweekly until day of device removal.

• Average Positive and Negative Syndrome Scale (PANSS) During the Study (Oral & Implant Phases)

  For group 1: Screening period, day -1, day 84, day 183; and for Group 2: Screening period, day -1, day 84, day 182, day 280, day 364.

• Average Clinical Global Impression-Improvement (CGI-I) Scale During the Implant Phase

  CGI-I assessments were conducted over the course of the study per the protocol schedule of assessments. For Group 1: day 7, 14, 28, 42, 70, 112,140, 68, 183 and for Group 2: day 7, 14, 28, 56, 84, 112,140, 168,182, 210, 238, 252, 280, 308, 336, 350, 364.

• Average Daily Risperidone Implant Output During the Implant Phase

  6-months and 12-months for groups 1 and 2 respectively. Remaining Risperidone measurements taken at the end of the Implant Phase.

Study Arms (2)

DLP-114 alpha-4 (6-months)

EXPERIMENTAL

Group 1: 6-month implant arm Oral phase: 3mg of Risperidone for 2 weeks Implant phase: 2 implants (360mg of Risperidone per implant) for 6 months

Combination Product: Risperidone

DLP-114 alpha-7 (12-months)

EXPERIMENTAL

Group 2: 12-month implant arm Oral phase: 3mg of Risperidone for 2 weeks Implant phase: 2 implants (435mg of Risperidone per implant) for 12 months

Combination Product: Risperidone

Interventions

Risperidone COMBINATION_PRODUCT

Risperidone Implant

Also known as: DLP-114

DLP-114 alpha-4 (6-months); DLP-114 alpha-7 (12-months)

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patients 18-70 years of age of both sexes diagnosed with schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual (DSM)-V who have been stable on oral risperidone (2mg-3mg) for at least 2 weeks.
• Patient (and/or a patient's authorized legal representative) has provided written informed consent
• Patient meets the following criteria:
• Outpatient status
• PANSS Total Score ≤ 80 at screening.
• A score of ≤ 4 on the following PANSS items:
• i. Conceptual disorganization ii. Suspiciousness iii. Hallucinatory behavior iv. Unusual thought content v. Hostility d. Clinical Global Impression Scale (CGI-S) ≤ 4 (moderately ill)\\Lack of clinically significant suicidal ideation or behavior; Columbia Suicide Severity Rating Scale (C-SSRS) score type of 4-5 require evaluation by mental health professional to ensure patient safety in study
• Body Mass Index (BMI) within the range of 18.5 to 40.0 kg/m2 (inclusive);
• Ability to understand the nature and objectives of the trial, including risks and adverse events, and be able to read, review and sign the informed consent document prior to conduct of any study procedures;
• Willing and able to comply with the requirements of the study protocol; including willingness to visit the clinical facility for all outpatient visits and confinement periods;
• Have suitable venous access for blood sampling.
• Patient is assessed by the Investigator to be symptomatically stable with regard to pre-existing medical conditions as evidenced by medical history, non-clinically significant findings on physical examination, vital signs, clinical laboratory evaluations (hematology, serum chemistries, and urinalysis) or 12-lead electrocardiogram (ECG). Subjects may continue on their current prescribed medication regimens to control pre-existing medical and psychiatric conditions (other than schizophrenia) including the use of prescribed PRN medications.

You may not qualify if:

• PANSS score at baseline is ≥ 20% change from screening.
• Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator
• Patient has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide.
• Patient experiencing acute depressive symptoms within the past 30 days, according to the Investigator's opinion, that required treatment with an antidepressant
• Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening.
• Have impaired hepatic (Alanine transaminase (ALT) /aspartate aminotransferase (AST) \>1.5 times higher than the upper limit of normal) or renal function (eGFR\<50 mL/min)
• Previously defined hypersensitivity to Risperidone
• History of neuroleptic malignant syndrome (NMS)
• Electroconvulsive therapy within 6 months of admission
• Requires current use of agents that are strong inhibitors and inducers of cytochrome P450;
• Known hypersensitivity or allergy to lidocaine or any local anesthetic agent of the amide type (local anesthetic used during implant and explant procedures);
• Presence of clinically significant skin disorders (such as, but not limited to, skin cancer, psoriasis, eczema, or atopic dermatitis), evidence of recent sunburn, scar tissue, tattoo, open sore, body piercing or branding at the intended implantation site that would interfere with the implantation procedure or interfere with implant site assessments as determined by the investigator;
• History of clinically significant hypersensitivity or allergic reactions;
• Known allergy or hypersensitivity to para-aminobenzoic acid (PABA);
• Known allergy or hypersensitivity to parabens, local anesthetics of the ester type, and sulfa drugs including antibiotics and thiazide diuretics;

Sponsors & Collaborators

• Delpor, Inc.: lead
• National Institute of Mental Health (NIMH): collaborator

Study Sites (2)

Collaborative Neuroscience Research

Long Beach, California, 90806, United States

Location

Segal Trials

Miami Lakes, Florida, 33016, United States

Location

MeSH Terms

Conditions

Schizophrenia

Interventions

Risperidone

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Eesha Gupta
• Organization: Delpor, Inc.

eesha.gupta@delpor.com

415-289-1770

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 1, 2020
• First Posted: June 5, 2020
• Study Start: April 1, 2021
• Primary Completion: February 10, 2023
• Study Completion: February 10, 2023
• Last Updated: December 27, 2024
• Results First Posted: December 27, 2024

Record last verified: 2024-12

Locations

US (2)